Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Immunology

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44341   clinical trials with a EudraCT protocol, of which   7370   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    141 result(s) found for: Immunology. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2010-023105-35 Sponsor Protocol Number: IC/VG/P01-2010 Start Date*: 2010-10-14
    Sponsor Name:Cantacuzino National Institute of Research and Development for Microbiology and Immunology
    Full Title: The Study of the Immunogenity and Reactogenity of Trivalent, Purified, Inactivated Influenza Vaccine for Parenteral Administration in Adults, for the 2010-2011 Season, Produced by Cantacuzino Natio...
    Medical condition: Healthy adult volunteers (2 age-groups: 18-60 years and >60 years old) are vaccinated in order to achieve protection against influenza virus infection with the vaccine containing the influenza viru...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000105-23 Sponsor Protocol Number: DYDRA001 Start Date*: 2019-03-01
    Sponsor Name:UZ Brussel
    Full Title: Oral dydrogesterone (OD) versus micronized vaginal progesterone (MVP) for luteal phase support (LPS) in IVF/ICSI: pharmacokinetics and the impact on the endometrium, the microbiota of the genital t...
    Medical condition: Female infertility
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001042-24 Sponsor Protocol Number: INFQ3001 Start Date*: 2015-05-27
    Sponsor Name:Abbott Biologicals B.V.
    Full Title: Randomized, Double-Blind, Active-Controlled Study in Adults to Assess the Safety and Immunogenicity of Abbott’s Candidate Quadrivalent Influenza Vaccine and its Non-Inferiority to Trivalent Influen...
    Medical condition: Prophylaxis of Influenza
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004862 10022005 Influenza viral infections HLT
    18.1 10022891 - Investigations 10062297 Immunology test PT
    18.1 10018065 - General disorders and administration site conditions 10065109 Reactogenicity event PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) LV (Completed) HU (Completed) LT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2006-003384-30 Sponsor Protocol Number: IR902-231 Start Date*: 2007-02-26
    Sponsor Name:The Immune Response Corporation
    Full Title: A Phase II Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for Multiple Sclerosis
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015876-86 Sponsor Protocol Number: SCB-004 Start Date*: 2010-04-20
    Sponsor Name:Southampton University Hospitals
    Full Title: An investigation into the mechanisms of action of a combined long acting beta agonist/inhaled corticosteroid (Seretide 500 accuhaler) on the bacterial colonisation, immunology and inflammation of p...
    Medical condition: Chronic Obstructive Pulmonary Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-004016-26 Sponsor Protocol Number: Clin_COVID-19_Corok Start Date*: 2021-10-18
    Sponsor Name:Meilahti Vaccine Research Center - Helsinki University Hospital
    Full Title: Substudy "Responses to Covid-19 vaccines" in research "Clinical picture, immunology, genetics and pathogenesis of COVID-19 infection"
    Medical condition: None
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005129-10 Sponsor Protocol Number: Elovaara09112014 Start Date*: 2015-01-27
    Sponsor Name:Irina Elovaara
    Full Title: Multiple Sclerosis and Menopause: the effect of hormone replacement therapy on clinical picture and immunology of multiple sclerosis
    Medical condition: Multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004852 10064137 Progression of multiple sclerosis LLT
    17.1 100000004852 10070425 Multiple sclerosis exacerbation LLT
    Population Age: Adults Gender: Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-007100-42 Sponsor Protocol Number: 15581 Start Date*: 2007-01-29
    Sponsor Name:Turku University Hospital
    Full Title: Viral Inception of Asthma: Prospective study from infancy to early school-age.
    Medical condition: First wheezing episode (=acute expiratory breathing difficulty) associated with rhinovirus infection in 3 to 23 -month-old children.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10047925 Wheezing expiratory LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-005450-30 Sponsor Protocol Number: ABI-MS-P01 Start Date*: 2014-01-08
    Sponsor Name:Medizinische Universität Innsbruck
    Full Title: Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment
    Medical condition: Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-002771-40 Sponsor Protocol Number: PIX-01 Start Date*: 2006-08-28
    Sponsor Name:S.G.O. Johansson, MD PhD Professor
    Full Title: Importance of IgE antibody fraction size on allergen sensitivity of basophils from cat allergic patients on Xolair. A pilot study.
    Medical condition: Allergic asthma and or rhinitis due to allergy to cat dander
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001072-15 Sponsor Protocol Number: COV001 Start Date*: 2020-03-26
    Sponsor Name:University of Oxford
    Full Title: A phase I/II study to determine efficacy, safety and immunogenicity of the candidate Coronavirus Disease (COVID-19) vaccine ChAdOx1 nCoV-19 in UK healthy adult volunteers
    Medical condition: COVID-19
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-004046-28 Sponsor Protocol Number: AUR-VCS-2016-02 Start Date*: 2018-05-23
    Sponsor Name:Aurinia Pharmaceuticals, Inc.
    Full Title: A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis
    Medical condition: Lupus Nephritis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038359 - Renal and urinary disorders 10025140 Lupus nephritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BG (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2020-002985-15 Sponsor Protocol Number: MOR202C205 Start Date*: 2020-10-12
    Sponsor Name:MorphoSys AG
    Full Title: A Phase IIa, Open-Label, 2-Arm Multicenter Clinical Trial to Evaluate the Efficacy, Safety and PK/PD of the Human Anti-CD38 Antibody MOR202 in Anti-PLA2R Antibody Positive Membranous Nephropathy (N...
    Medical condition: Anti-PLA2R antibody positive membranous nephropathy (aMN)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10027170 Membranous nephropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2006-000985-34 Sponsor Protocol Number: 001:CD40L Start Date*: 2006-06-15
    Sponsor Name:Clinical Immunology Division
    Full Title: A Phase I-IIa Study of Dose escalating Intravesical AdCD40L instillation in Urinary Bladder Carcinoma
    Medical condition: Urinary bladder cancer is an attractive target for immunostimulating gene therapy because it is sensitive for immunotherapy as demonstrated by the life-prolonging effect of bacillus Calmette-Guérin...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-000946-37 Sponsor Protocol Number: R668-AD-1121 Start Date*: 2012-06-13
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: A randomized, double-blind, parallel-group, placebo-controlled study to assess the safety of REGN668 administered concomitantly with topical corticosteroids to patients with moderate-to-severe Atop...
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10040785 - Skin and subcutaneous tissue disorders 10003639 Atopic dermatitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001356-20 Sponsor Protocol Number: 0602001 Start Date*: 2006-06-05
    Sponsor Name:Reckitt Benckiser (UK) Limited
    Full Title: A preliminary single dose, three-way, double-blind, placebo-controlled crossover study of intravenous buprenorphine/naloxone in the treatment of neuropathic pain of diabetic neuropathy origin.
    Medical condition: Neuropathic pain
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2013-001393-19 Sponsor Protocol Number: 003:TCELL Start Date*: 2014-04-08
    Sponsor Name:Uppsala university
    Full Title: CD19-targeting 3rd generation CAR T cells for refractory B cell malignancy - a phase I/IIa trial.
    Medical condition: CD19+ B cell lymphoma or leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023185-42 Sponsor Protocol Number: S105AMCNilotinibSpA Start Date*: 2011-04-21
    Sponsor Name:Academic Medical Center, Division of Clinical Immunology and Rheumatology
    Full Title: Proof-of-concept double-blind, placebo-controlled, randomized clinical trial with nilotinib in spondyloarthritis
    Medical condition: Active axial and peripheral spondyloarthritis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010955-29 Sponsor Protocol Number: 10031983 Start Date*: 2009-07-13
    Sponsor Name:Division of Clinically Immunology and Rheumatology, AMC
    Full Title: Prevention of clinically manifest rheumatoid arthritis by B cell directed therapy in the earliest phase of the disease.
    Medical condition: Pre-clinical RA patients with a high risk on developing the disease.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018596-24 Sponsor Protocol Number: 6311 Start Date*: 2011-05-19
    Sponsor Name:Oxford Radcliffe Hospital NHS Trust
    Full Title: Assessment of Salmonella Typhim Vi(TM) vaccine (Sanofi Pasteur MSD) for the investigation of selective antibody deficiency to polysaccharide.
    Medical condition: Suspected primary antibody deficiency states will be investigated
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 13 13:15:00 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA